Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

Tofacitinib treatment is used for teenagers with alopecia areata.

Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Latanoprost helps pig hair follicles grow faster by keeping them in the growth phase longer.

Apremilast improved symptoms in patients with severe skin conditions.

The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.

The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

New steroids were effective in blocking male hormone receptors in hamster prostates.

Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

A reliable method was developed to measure aristolochic acid-I in rat blood.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

PFD patch helps laser tattoo removal, trichoscopy diagnoses AGA, and serum boosts SOD activity.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.